GoodRx (NASDAQ:GDRX) Trading Up 3.2%

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price rose 3.2% during trading on Tuesday . The stock traded as high as $6.76 and last traded at $6.76. Approximately 394,534 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 1,572,341 shares. The stock had previously closed at $6.55.

Wall Street Analysts Forecast Growth

GDRX has been the topic of several analyst reports. TD Cowen boosted their target price on GoodRx from $12.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Truist Financial boosted their target price on GoodRx from $7.50 to $8.00 and gave the stock a “hold” rating in a report on Friday, March 1st. Wells Fargo & Company raised GoodRx from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $7.50 to $10.00 in a report on Monday, March 25th. The Goldman Sachs Group boosted their target price on GoodRx from $6.50 to $7.50 and gave the stock a “neutral” rating in a report on Friday, March 1st. Finally, SVB Leerink initiated coverage on GoodRx in a report on Monday, February 26th. They issued an “outperform” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.78.

GoodRx Stock Performance

The business has a fifty day simple moving average of $6.88 and a two-hundred day simple moving average of $6.19. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.85. The company has a market cap of $2.57 billion, a P/E ratio of -324.84, a P/E/G ratio of 3.57 and a beta of 1.42.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. The company had revenue of $196.64 million for the quarter, compared to the consensus estimate of $195.59 million. On average, sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its holdings in GoodRx by 2,602.7% in the third quarter. Tower Research Capital LLC TRC now owns 6,919 shares of the company’s stock valued at $39,000 after acquiring an additional 6,663 shares during the period. Ensign Peak Advisors Inc purchased a new stake in GoodRx in the third quarter worth about $42,000. Citigroup Inc. increased its position in GoodRx by 301.7% in the third quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after buying an additional 6,006 shares in the last quarter. Creative Planning purchased a new stake in GoodRx in the fourth quarter worth about $50,000. Finally, Quadrature Capital Ltd purchased a new stake in GoodRx in the third quarter worth about $58,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.